ACTRN12611000498998终止2 期
Adult patients testing eculizumab for atypical hemolytic-uremic syndrome for safety and efficacy
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients must be willing to give written informed consent.
- •Patients must be over 18 years of age with a diagnosis of atyipcal hemolytic-uremic syndrome.
- •Patients exhibit thrombocytopenia, hemolysis and elevated serum creatinine.
排除标准
- •Chronic dialysis.
- •Prior eculizumab use or hypersensitivity to eculizumab, to murine proteins or to one of the excipients.
研究者
相似试验
进行中（未招募）
2 期
Study to evaluate if eculizumab is efficient and safe enough to be used for treatment of children with atypical hemolytic-uremic syndromeAtypical Hemolytic-Uremic SyndromeRenal and Urogenital - Kidney diseaseACTRN12611000461998Alexion Pharmaceuticals Australasia Pty Ltd15
已完成
2 期
An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic SyndromeAtypical Hemolytic-Uremic SyndromeNCT01194973Alexion Pharmaceuticals, Inc.44
已完成
3 期
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)Refractory Generalized Myasthenia GravisNCT01997229Alexion Pharmaceuticals, Inc.125
已完成
2 期
E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria PatientsParoxysmal Nocturnal HemoglobinuriaNCT01194804Alexion Pharmaceuticals, Inc.27
招募中
不适用
Development of a Pathogen Blood Test for patients with Lyme-like symptomsSuspected Lyme DiseaseNeurological conditionsArthritisInfection - Studies of infection and infectious agentsNeurological - Neurodegenerative diseasesMusculoskeletal - Other muscular and skeletal disordersACTRN12615000202561ational Institute of Integrative Medicine1,000